Impact of HIV Infection and HAART on Serum Lipids in Men | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Grunfeld C, Kotler DP, Shigenaga JK.  et al.  Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.  Am J Med.1991;90:154-162.Google Scholar
2.
Grunfeld C, Pang M, Doerrler W.  et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.  J Clin Endocrinol Metab.1992;74:1045-1052.Google Scholar
3.
Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.  N Engl J Med.1992;327:329-337.Google Scholar
4.
Shor-Posner G, Basit A, Lu Y.  et al.  Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection.  Am J Med.1993;94:515-519.Google Scholar
5.
Carr A, Samaras K, Burton S.  et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.  AIDS.1998;12:F51-F58.Google Scholar
6.
Behrens G, Dejam A, Schmidt H.  et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.  AIDS.1999;13:F63-F70.Google Scholar
7.
Berthold HK, Parhofer KG, Ritter MM.  et al.  Influence of protease inhibitor therapy on lipoprotein metabolism.  J Intern Med.1999;246:567-575.Google Scholar
8.
Carr A, Samaras K, Thorisdottir A.  et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus.  Lancet.1999;353:2093-2099.Google Scholar
9.
Dong KL, Bausserman LL, Flynn MM.  et al.  Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).  J Acquir Immune Defic Syndr.1999;21:107-113.Google Scholar
10.
Periard D, Telenti A, Sudre P.  et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors.  Circulation.1999;100:700-705.Google Scholar
11.
Roberts AD, Muesing RA, Parenti DM.  et al.  Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients.  Clin Infect Dis.1999;29:441-443.Google Scholar
12.
Bonnet F, Saves M, Droz C.  et al.  Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.  J Acquir Immune Defic Syndr.2000;25:199-200.Google Scholar
13.
Mulligan K, Grunfeld C, Tai VW.  et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.  J Acquir Immune Defic Syndr.2000;23:35-43.Google Scholar
14.
Henry K, Melroe H, Huebsch J.  et al.  Severe premature coronary artery disease with protease inhibitors [letter].  Lancet.1998;351:1328.Google Scholar
15.
Bozzette SA, Ake CF, Tam HK.  et al.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.  N Engl J Med.2003;348:702-710.Google Scholar
16.
Friis-Møller F, Weber R, D'Arminio Monforte A.  et al.  Exposure to HAART is associated with an increased risk of myocardial infarction. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 130.
17.
Staszewski S, Gallant JE, Pozniak AL.  et al.  Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 564b.
18.
Henry K, Melroe H, Huebesch J.  et al.  Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities [letter].  Lancet.1998;352:1031-1032.Google Scholar
19.
Allain CC, Poon LS, Chan CSG.  et al.  Enzymatic determination of total serum cholesterol.  Clin Chem.1974;20:470-475.Google Scholar
20.
Warnick GR, Albers JJ. A comprehensive evaluation of heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.  J Lipid Res.1978;19:65-76.Google Scholar
21.
Rifai N, Iannotti E, DeAngelis K, Law T. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method.  Clin Chem.1998;44:1242-1250.Google Scholar
22.
Giorgi JV, Cheng HL, Margolick JB.  et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets.  Clin Immunol Immunopathol.1990;55:173-186.Google Scholar
23.
AIDSinfo: A Service of US Department of Health and Human Services.  Overview of guidelines. Available at: http://www.aidsinfo.nih.gov/guidelines. Accessibility verified May 16, 2003.
24.
US Department of Health and Human Services, National Center for Health Statistics.  Third National Health and Nutrition Examination Survey, 1998-1999 Public Use Data File [CD-ROM]. Hyattsville, Md: Centers for Disease Control and Prevention; 1996.
25.
Johnson CL, Rifkind BM, Sempos CT.  et al.  Declining serum total cholesterol levels among US adults.  JAMA.1993;269:3002-3008.Google Scholar
26.
 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA.2001;285:2486-2497.Google Scholar
Original Contribution
June 11, 2003

Impact of HIV Infection and HAART on Serum Lipids in Men

Author Affiliations

Author Affiliations: University of Pittsburgh, Pittsburgh, Pa (Drs Riddler, Evans, and Kingsley); State University of New York at Buffalo (Dr Smit); Johns Hopkins University, Baltimore, Md (Drs Cole and Dobs, and Ms Li); Northwestern University, Chicago, Ill (Drs Chmiel and Palella); and University of California, Los Angeles (Dr Visscher).

JAMA. 2003;289(22):2978-2982. doi:10.1001/jama.289.22.2978
Abstract

Context Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values.

Objective To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation.

Design, Setting, and Participants The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002.

Main Outcome Measures Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit.

Results Among the 50 men, notable declines in mean serum TC (–30 mg/dL [−0.78 mmol/L]), HDL-C (–12 mg/dL [−0.31 mmol/L]), and LDL-C values (–22 mg/dL [−0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (−0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL).

Conclusions Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.

×